Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) FCF Margin (2016 - 2026)

Heron Therapeutics filings provide 13 years of FCF Margin readings, the most recent being 5.56% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 1752.0% to 5.56% in Q1 2026 year-over-year; TTM through Mar 2026 was 13.84%, a 169.0% increase, with the full-year FY2025 number at 18.02%, down 122.0% from a year prior.
  • FCF Margin hit 5.56% in Q1 2026 for Heron Therapeutics, up from 22.63% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 8.96% in Q3 2024 to a low of 191.77% in Q1 2022.
  • Median FCF Margin over the past 5 years was 29.77% (2025), compared with a mean of 52.8%.
  • Biggest five-year swings in FCF Margin: surged 17822bps in 2022 and later plummeted -3689bps in 2024.
  • Heron Therapeutics' FCF Margin stood at 126.38% in 2022, then soared by 105bps to 6.44% in 2023, then plummeted by -573bps to 30.45% in 2024, then grew by 26bps to 22.63% in 2025, then skyrocketed by 75bps to 5.56% in 2026.
  • The last three reported values for FCF Margin were 5.56% (Q1 2026), 22.63% (Q4 2025), and 3.48% (Q3 2025) per Business Quant data.